Exercise for AF, drugs have more than one effect, AI bots and the future of medicine, and the good and bad news about prognosis in HF are the topics John Mandrola, MD, discusses in this week’s podcast.

This podcast is intended for healthcare professionals only.

To read a partial transcript or to comment, visit: https://www.medscape.com/twic

I. AF and Exercise

• Aerobic Exercise Can Reduce AF Frequency, Severity: ACTIVE-AF https://www.medscape.com/viewarticle/957322
• An Exercise and Physical Activity Program in Patients With Atrial Fibrillation: The ACTIVE-AF Randomized Controlled Trial https://www.jacc.org/doi/full/10.1016/j.jacep.2022.12.002
• Early Rhythm-Control Therapy in Patients with Atrial Fibrillation https://www.nejm.org/doi/full/10.1056/NEJMoa2019422

II. GLP-1 Inhibitors and Retinopathy

• Eye Check Important Before Starting Semaglutide for Diabetes https://www.medscape.com/viewarticle/987418
• Glucagon-like peptide 1-receptor agonists and A1c: Good for the heart but less so for the eyes? https://doi.org/10.1016/j.dsx.2022.102696

III. AI Bot Passes USMLEs

• AI Bot ChatGPT Passes US Medical Licensing Exams Without Cramming – Unlike Students https://www.medscape.com/viewarticle/987549
• Performance of ChatGPT on USMLE: Potential for AI-Assisted Medical 2 Education Using Large Language Models https://www.medrxiv.org/content/10.1101/2022.12.19.22283643v2.full.pdf
• Tyler Cowen Comments -- GPT and my own career trajectory https://marginalrevolution.com/marginalrevolution/2023/01/gpt-and-my-own-career-trajectory.html

IV. HF Prognosis

• Temporal trends in the incidence of malignancy in heart failure: a nationwide Danish study https://doi.org/10.1093/eurheartj/ehac797

You may also like:

Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine

The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington

Questions or feedback, please contact [email protected]